Moving up the Biotechnology value chain
|
|
||
|
Source : http://knowledge.wharton.upenn.edu
Activity:
0 comments
199 views
last activity : 07 06 2010 20:18:04 +0000
|
||
|
|
Since the introduction of generic drugs in Brazil five years ago, the country's pharmaceutical industry has undergone a transformation. Generic drugs have been steadily gaining market share and today represent 11.6% of total production. Their rise has led to a decline in the influence of major multinational drug companies that sell branded products in the domestic market.
Generic drugs, however, are not the only danger confronting these multinationals. In an attempt to negotiate discounted prices, the Brazilian government is threatening to violate the patents on medications used to treat AIDS.
That threat alone, say the multinationals, will lead big drug companies to reduce their investments in Brazil's pharmaceutical sector.
Because of the continued danger that patents will be violated, employment in Brazil's scientific research sector has dropped to about 20,000 from a total of 24,000 jobs in 1999
|
|
|
|
|
|
|
|
|
|
Kaushik is right, research is a field where most of the inventions receive recognition after the person responsiblefor it is dead, This because of the failure rates, dealing with life science is not an easy job, every time you get the unexpected... |
According to me there is a good news that the financial crisis does not have an incremental effect on overall industry productivity (biotech + pharma). As compared to the performance of the NASDAQ biotechnology index to the performance of NASDAQ... |
yes Mr. karamjeet its very true that biotechnology will be the driving force behind the agriculture and the farmers of the country who are the backbone of the country, and biotechnology is seeing a upward movement lately, and in next decade it will... |
